Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1404&sort=end_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=end_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=end_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=end_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1403&sort=end_date" }, "data": [ { "type": "Grant", "id": "15232", "attributes": { "award_id": "1K01HL174822-01", "title": "Endothelial S1PR1 promotes lung repair in post-viral ARDS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 20693, "first_name": "Roya", "last_name": "Kalantari", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 161240, "principal_investigator": { "id": 31816, "first_name": "Patricia Louise", "last_name": "Brazee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Viral respiratory infections, such as influenza and SARS-CoV2, frequently lead to acute respiratory distress syndrome (ARDS), a condition with a mortality up to 46%. Endothelial injury, dysfunction and the resultant vascular hyperpermeability contribute to the severity of ARDS, persistence of lung injury, and dysregulated repair with the development of fibrosis. While sphingosine-1-phosphate receptor 1 (S1PR1) is a key protective signaling axis on endothelial cells, the role of S1PR1 signaling in the resolution of lung injury in post-viral ARDS has not been well explored. The objective of this application is to define endothelial S1PR1-dependant pathways which promote the re-alveolarization of the post-viral lung needed to prevent morbid fibrotic outcomes. We hypothesize that endothelial S1PR1 signaling promotes productive lung repair after viral infection via BMP2 mediated support of the epithelial niche. These preliminary findings a new facet to the pleotropic benefits of EC S1PR1 beyond its established role in limiting vascular hyperpermeability and highlight a need to comprehensively validate the therapeutic potential of augmenting S1PR1 expression to limit post-viral pulmonary fibrosis. We will test this hypothesis via two specific aims: 1) determine the mechanism of endothelial S1PR1 mediated epithelial repair after viral-induced ARDS, and 2) determine how EC S1PR1 regulation can be therapeutically augmented to attenuate post-viral fibrosis. The proposed research will reveal novel links between EC S1PR1 and epithelial regeneration and differentiation after viral infection and identify regulators of endothelial function which can be therapeutically targeted to attenuate post- viral fibrosis. Dr. Brazee’s long-term goal is to be an independent basic and translational investigator with a research program aimed at understanding the contributions of the endothelium in supporting productive lung repair pathways. The proposed K01 research aims utilize prior training in mouse models of influenza virus infection, fibrotic lung disease, and fundamental molecular biology techniques. In addition, the project will necessitate advanced training in vascular and epithelial biology, G-protein coupled receptor (GPCR) signaling, and translational modeling of human disease using human derived 3D organoids and precision cut lung slices. Successful completion of these aims, together with continued professional development, will provide the proficiencies necessary to establish a productive research program and an impactful career as an independent R01-funded investigator.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15236", "attributes": { "award_id": "1K08AI178093-01A1", "title": "SARS-CoV-2 immune responses in patients with lymphoma", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6125, "first_name": "Timothy A.", "last_name": "Gondre-Lewis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-23", "end_date": "2029-07-31", "award_amount": 192888, "principal_investigator": { "id": 31821, "first_name": "Andres", "last_name": "Chang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients have immune system deficits that arise from the cancer and are aggravated by lymphoma therapies, placing them at higher risk of morbidity and mortality after infection with viruses like influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients are strongly recommended to get vaccinated and boosted with SARS-CoV-2 mRNA vaccines, but antibody responses after vaccination in these patients are often impaired. SARS-CoV-2 vaccines also elicit T cell responses in healthy individuals that may be protective but previous studies indicate that T cells from NHL/CLL patients are also dysfunctional. Under the mentorship of Drs. Rafi Ahmed and Jonathon Cohen, I have assembled a cohort of over 600 NHL/CLL patients with over 1,300 longitudinal blood samples paired with clinical data that I have used to study the immune responses in this patient population. Using this cohort, I showed that most patients have lower antibody responses after SARS-CoV-2 vaccination than otherwise healthy individuals and that antibody responses correlate at least partly with lymphoma therapies. I have also shown that some patients produce spike-specific CD4+ and CD8+ T cells after vaccination. The longitudinal, antigen-specific CD4+ and CD8+ T cell responses after vaccination and infection have not been well characterized in NHL/CLL patients. I hypothesize that these patients have alterations in their CD4+ and CD8+ T cell responses after antigen stimulation, which are dependent on the underlying lymphoma subtype and lymphoma therapy. This proposal has 3 goals: 1) To evaluate the generation, differentiation, breadth, and persistence of SARS- CoV-2-specific CD4+ T cell responses in NHL/CLL patients after vaccination and infection using functional assays and single cell sequencing technologies; 2) To define the primary and memory SARS-CoV-2-specific CD8+ T cell responses after vaccination and infection through functional assays and single cell sequencing technologies; and 3) to support my transition from a trainee in Dr. Ahmed’s laboratory to leading an independent research program. Successful completion of these studies will provide in-depth knowledge of the generation, evolution, breadth, and persistence of antigen-specific T cell responses in NHL/CLL patients after vaccination and infection. This knowledge will facilitate the design of interventions that may improve vaccine responses in these and other immunosuppressed patients, protecting them from potentially life-threatening viral infections like SARS-CoV-2 and influenza. Moreover, the insights on the generation and maintenance of adaptive immune responses against novel antigens obtained from these studies could help fuel the development of better cancer immunotherapies.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15238", "attributes": { "award_id": "1U01IP001265-01", "title": "IP24-045, SEAPREP: Seattle Pandemic Preparedness Cohort", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Immunization and Respiratory Diseases (NCIRD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 3874443, "principal_investigator": { "id": 11527, "first_name": "Helen Ying-hui", "last_name": "Chu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Community-based surveillance studies of respiratory viruses provide the opportunity for early viral detection and situational awareness, and may inform early public health efforts to mitigate the transmission of respiratory viruses, as was evidenced by the SARS-CoV-2 pandemic. Case-ascertained household transmission studies are an efficient and epidemiologically rich method to study respiratory virus transmission. Our team of investigators has deep expertise in community surveillance and case-ascertainment trials of respiratory viruses. Our group of collaborators include specialists in infectious diseases, epidemiology, biostatistics, virology, immunology, and infectious disease modeling. In 2018, we developed the infrastructure for a pandemic preparedness platform in Seattle, Washington, leading to the first identification of SARS-CoV-2 community transmission in the United States. We have developed innovative methods for fully remote observational studies of respiratory viruses in households, and have built a logistics and laboratory insfrastructure for rapid delivery and pickup of biospecimens, multiplex testing for a panel of respiratory pathogens, in-depth immunologic characterization, and whole genome sequencing and visualization. In this study, we propose to build on these platforms to conduct the following studies. First, we propose a prospective longitudinal cohort study of 2000 children and adults in the Seattle area, with weekly symptom screening and collection of nasal swabs for respiratory illness. We will conduct multi-pathogen testing for respiratory viruses and whole genome sequencing for RSV, SARS-CoV-2, and other respiratory viruses. We will calculate incidence, assess epidemiology and burden of respiratory viruses, measure participant knowledge, attitudes and perceptions, and measure the effectiveness of interventions in prevention of disease. We additionally propose to perform in-depth immunologic assessments by collection of serum samples longitudinally in a subset of individuals to understand antibody kinetics over the course of multiple seasons, and the effects of vaccines and infections on antibody titers across age groups. For our second study, we propose to conduct a case-ascertained household transmission study to understand transmission dynamics of SARS-CoV-2, RSV, and other viruses. Index cases will be enrolled remotely along with their household members, for serial self-swab collection for a period of two weeks after enrollment. We propose collection of environmental samples within a subset of households. Molecular testing and sequencing will be performed for SARS-CoV-2, RSV, and other viruses, as indicated, allowing for calculation of household attack rates, serial intervals, and risk factors for within household transmission for known and novel pathogens. These proposed studies will provide real-time situational awareness of community respiratory epidemiology, and our team has the experience and expertise to pivot for identification of novel pathogens and pandemic response.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15240", "attributes": { "award_id": "1K23HL168161-01A1", "title": "K23 Resubmission - Impact of adoptive T cell therapy on immunity to SARS-CoV-2 after bone marrow transplant", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24472, "first_name": "LISBETH A", "last_name": "WELNIAK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-15", "end_date": "2029-07-31", "award_amount": 160518, "principal_investigator": { "id": 31825, "first_name": "Susan", "last_name": "Conway", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1167, "ror": "", "name": "CHILDREN'S RESEARCH INSTITUTE", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true }, "abstract": "The overarching goal of this proposal is the development of the candidate into an independent investigator in the field of immune modulatory cell therapy for critically ill children, particularly those post hematopoietic stem cell transplant (HSCT). With her clinical and research background in pediatric critical care and T cell immunotherapy, she is ideally positioned to fully realize the benefits of an NIH Mentored Career Development Award. This research proposal seeks to establish the safety and preliminary efficacy of adoptive immunotherapy with donor-derived SARS-CoV-2-specific T cells (CST) for prophylaxis against SARS-CoV-2 infection in patients post HSCT by conducting an FDA- and IRB-approved phase I clinical trial (NCT 05141058) and to develop CSTs genetically engineered to maintain antiviral activity in the presence of the commonly used lymphodepleting agent, alemtuzumab. The specific aims of the proposal are: 1) to determine whether infusion of donor-derived CSTs safely enhances antiviral immunity to SARS-CoV-2 in patients early (<4 months) post HSCT, and 2) to genetically engineer CSTs to retain antiviral activity in vitro in the presence of alemtuzumab. Together, these aims will establish the safety and preliminary efficacy of CST prophylaxis in the post HSCT population and lay the foundation for a “next generation” of virus-specific T cells (VST) engineered to resist immunosuppressive peri- transplant drugs. In addition, they will develop the candidate's expertise in T cell immunobiology, high throughput sequencing, gene editing, and early phase clinical trials. The candidate has assembled an outstanding advisory team who are highly qualified to guide her in the pursuit of her career and research goals. Her primary mentor and co-mentor, Drs. Catherine Bollard and Michael Keller, are world-renowned experts in immune modulatory cellular therapy and T cell immunobiology. Dr. Matthew Porteus, a pioneer in the field of gene therapy, will guide her work developing genetically engineered CSTs. In addition, Dr. Patrick Hanley, Director of the Good Manufacturing Processes Laboratory at Children's National Hospital, will oversee production of the CST product (IND 27588); Dr. Rick Jones will advise and oversee trial conduct at Johns Hopkins Medical Institutions (JHMI); and Dr. Wei Li will provide bioinformatic support for both CRISPR and high throughput sequencing experiments. A selection of focused coursework and seminars will facilitate investigator independence by the end of the award period. The candidate will benefit from a superb academic environment and extensive resources available through the Center for Cancer and Immunology Research, the Genetic Medicine Research Center, and the Clinical and Translational Science Institute at Children's National, as well as from in-person training in gene editing in the Porteus laboratory. In summary, this proposal describes a plan that is relevant, feasible, and will provide the necessary mentorship and training to promote the candidate's development into an independent clinician scientist in the field of cellular immune modulatory therapy.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15244", "attributes": { "award_id": "1F30MH136702-01", "title": "Mobile Crisis Workforce Pipeline: Meeting the Needs of Illinois", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26585, "first_name": "Maggie", "last_name": "Sweeney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 41241, "principal_investigator": { "id": 31832, "first_name": "Jeremy David", "last_name": "Fine", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has underscored the need for robust mental health services in the United States (US). In contrast, the mental health workforce is shrinking. Lack of resources has led to patients “boarding” for days in the Emergency Department (ED) while they await inpatient hospital beds. In attempt to address these issues, federal and state policymakers have recently enacted policies to improve the Nation’s mental health crisis care infrastructure. One such law changed the phone number for the National Suicide Prevention Lifeline (NSPL) to “988.” This simple number created an unprecedented demand for psychiatric crisis professionals who can respond to callers deemed to be at imminent risk of harm to themselves or others. The Substance Abuse and Mental Health Services Administration (SAMHSA) has put forth Mobile Crisis Units (MCUs) as a solution to this problem. MCUs are a psychiatric service that meets individuals in crisis wherever they are in the community to de-escalate, triage, and refer them to additional services. They represent a way to ensure NSPL callers can receive care in the least restrictive setting, thus preventing unnecessary hospitalization. According to the SAMSHA model, MCUs are two person teams composed of a mental health professional and a certified peer provider (i.e. a Certified Recovery Support Specialist [CRSS]). Many states must now significantly expand their mental health crisis workforce to effectively meet the needs of their citizens and follow SAMHSA’s recommendations. Illinois (IL) is an example of a state that has enacted policies designed to fill this gap. Two programs, the CRSS Success Program (CRSS-SP) and Program 590, were designed to increase the workforce of CRSSs able to work on MCUs and increase the number of MCUs in the state, respectively. These relatively new programs have yet to be evaluated on how effectively they are able to grow the state’s MCU workforce. Systems thinking is a framework that seeks to solve complex problems by understanding how parts of a system function to produce outcomes. Methods grounded in systems thinking, such as Group Model Building (GMB) and Simulation Modeling (SM), have a proven track record for effectively generating policies that solve healthcare workforce issues, but they have yet to be used in the context of the MCU workforce pipeline. The objectives of this study are therefore to 1) use GMB to create a map of Illinois’s MCU workforce pipeline system and evaluate if this method is effective in this context, 2) evaluate data from the CRSS-SP and Program 590 to determine which factors increase the likelihood that CRSSs and MHPs obtain and retain employment at MCUs, and 3) use SM to test policies that will help the state meet its MCU workforce needs. The recommendations generated by this study will be given to state government officials so they can be used to improve the lives of individuals in IL experiencing mental health crises.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15249", "attributes": { "award_id": "1K01AT012650-01A1", "title": "Culturally tailoring a mindfulness meditation mobile app to reduce psychological distress in African American adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 23034, "first_name": "Peter Daniel", "last_name": "Murray", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-09", "end_date": "2029-07-31", "award_amount": 151672, "principal_investigator": { "id": 31836, "first_name": "Jennifer Logan", "last_name": "Green", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 775, "ror": "https://ror.org/0264fdx42", "name": "San Diego State University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This K01 is a mixed methods research project in collaboration with an industry partner (i.e., Healthy Minds Innovations) and will be conducted across three aims during a 5-year comprehensive training program. In this innovative proposal, the candidate has identified a mentorship team and training goals to facilitate their transition to an independent research career focused on achieving health equity and advancing mind-body research by delivering culturally tailored digital health interventions to improve mental health and well-being in underserved populations. Background: African American (AA) adults are 20% more likely to report serious psychological distress (e.g., stress, anxiety, depression) compared to white adults. Racial discrimination, a significant source of stress in AA adults, increases psychological distress. AA adults lack access to quality mental health care and the compounding impact of the COVID-19 pandemic may further exacerbate mental health disparities. Reducing psychological distress and increasing access to mental health care for AA adults is a public health emergency. Commercially available mindfulness meditation mobile apps may be an effective and efficient solution because they improve psychological distress, are highly scalable and can increase access to care. However, most are not culturally tailored (i.e., include groups’ unique experiences, values, and beliefs). Culturally tailoring mindfulness meditation apps can enhance engagement and efficacy in racial/ethnic minority populations. Specific aims and research design: The goal of Aim 1 is to inform the development of an app prototype via focus groups (N=4, 5 participants each) in AA adults (half meditators, half non-meditators). The goal of Aim 2 is to culturally tailor a commercial mindfulness meditation app (Healthy Minds Program app) through a User-Centered Design (UCD) workshop. AA adults (N=8) will attend a virtual half-day UCD workshop where they will co-design an app prototype. After the prototype is built, participants will test it for 1 week and complete an exit interview to refine the app. Aim 3 will determine the feasibility of the culturally tailored prototype app following predetermined benchmarks. AA adults with elevated stress (N=72) will be randomized to use HMP or a health education app (The Wellness App) for 8 weeks. Psychological distress, race-related stress, mindfulness, and self- compassion will be measured at pre-, mid-, and post-intervention. Acceptability (ability to recruit, satisfaction, continued use, appropriateness) will be assessed with a post-intervention satisfaction survey. Demand (adherence to treatment) will be measured by objective app usage data (sessions/minutes completed) and attrition rate. Mentoring and training: A team of expert mentors and advisors (Vranceanu, Burnett-Zeigler, Gallo, and Roesch) will oversee the progress of this study and contribute to mentoring the candidate across 4 training goals aimed to develop expertise in: 1) mental health disparities, 2) cultural tailoring methods, 3) digital clinical trials, and 4) qualitative and mixed methods research and advanced statistics. This proposal aligns with NCCIH’s funding priorities including the development of feasible mobile health (mHealth) mind- body interventions and reducing health disparities. Impact: Collectively, this career development award will serve as a strong foundation toward the candidate’s independent research career and provides an innovative solution to improve access to mental health care for AA adults.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15257", "attributes": { "award_id": "1R01AI179709-01A1", "title": "Immunogenetics of COVID-19 Immune Response", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26918, "first_name": "Michelle Marie", "last_name": "Arnold", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 814873, "principal_investigator": { "id": 31845, "first_name": "Richard B", "last_name": "Kennedy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "This application is a request for funding of a vaccine immunogenetics research program focused on identifying critical genetic and phenotypic determinants of COVID-19 infection and/or vaccination-induced immunity by examining associations between gene polymorphisms, HLA allelic variation, and clinical phenotypes and inter- individual variations in immune response to COVID-19. Our laboratory has done significant work delineating the effect of gene polymorphisms on mumps, measles, rubella, influenza, and smallpox vaccine immune responses. Our research demonstrates that variations in immune responses to viral vaccines are multigenic and not a single dominant allele model and that the genetic contribution to such variations in immune responses can be quantified. Informed by insights from these studies and given the public health importance of the ongoing SARS-CoV-2 pandemic, we now turn our attention to understanding genetic associations with COVID-19-induced immune responses (regardless of whether they are vaccine or infection-induced, or a result of hybrid immunity). The most thorough and efficient study for such purposes is a comprehensive discovery/replication genome-wide association study (GWAS), to which we will add a phenome association study (PheWAS) followed by a more complete characterization of distinct immune effector mechanisms believed to contribute to protective immunity. Our studies will identify gene polymorphisms and pathways having the largest or most critical impact on inter-individual variations in immunity among subjects, and how comorbidities (phenotypes) contribute to these variations. Our Specific Aims are to 1) perform a large, genome-wide association study to identify novel genetic associations between SNPs and HLA alleles and inter-individual variations in the humoral immune response to COVID-19 infection or vaccination; identify polygenic risk scores predictive of antibody response; replicate the findings in an independent cohort; evaluate significant findings in a cohort with documented infection and no vaccination; 2) conduct a phenome-wide association study to quantify the effect of additional subject characteristics (e.g., age, sex, race, ethnicity, BMI), comorbidities, and phecodes (clusters of ICD10 codes) on the antibody response to COVID-19 vaccines; and 3) Evaluate the effect of genetic variation and host factors on T cell and B cell markers of immune response following vaccination. These aims will allow us to comprehensively define how inter-individual variations in immune responses to COVID-19 vaccine are influenced by gene polymorphisms and host characteristics. Notably, despite the public health implications, there are no population-based studies identifying associations between COVID-19 vaccine immune response and genome-wide SNPs or clinical phenotypes. Our study is carefully designed to be rigorous and produce robust, unbiased, and reproducible results applicable to the US population.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15259", "attributes": { "award_id": "1U01IP001238-01", "title": "IP24-045, PREVENT: Preparedness through Respiratory Virus Epidemiology and Community Engagement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Immunization and Respiratory Diseases (NCIRD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 5753431, "principal_investigator": { "id": 23572, "first_name": "LOUISE CHANG", "last_name": "LAURENT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Monitoring of the incidence, morbidity, and mortality of respiratory infections has largely been performed by collecting and analyzing data from hospitals and clinical laboratories. While these data sources provide valuable information on risk factors, incidence, therapeutic response, and outcomes of severe disease, they do not reflect the range of potential clinical presentations and courses of disease, factors that increase or decrease the risk of community transmission, and the impact of disease on education and employment. We therefore propose to create “PREVENT: Preparedness through Respiratory Virus Epidemiology and Community Engagement,” which will serve as one of the CDC Pandemic Preparedness Network Cohorts and the Network’s Data Hub. We will participate in Components A1, A2, B, and C, with a catchment that spans San Diego County in HHS Region 9 adjacent to the U.S./Mexico border. Our relevant experience includes establishment of innovative programs for large-scale COVID-19 clinical testing, environmental surveillance through monitoring of wastewater and surface swabs, viral genome sequencing, and monitoring of immunity using co-created community-based sample collection strategies that are highly accessible and culturally sensitive. Major PREVENT activities will include: Component A1: We will enroll and retain a diverse longitudinal cohort of 2,000 individuals for: weekly symptom screening; surveys on knowledge, attitudes, and behaviors related to preventative measures; extraction of outcome and vaccination data from electronic health records and immunization information systems; and collection of follow-up data from participants on use of preventative/therapeutic measures and healthcare resources, missed school/work, symptom type/duration, and long-term sequelae. Symptomatic swabs will be collected and tested for 20 high-priority respiratory pathogens. Viral genome sequencing will be performed on a subset of samples using targeted and metatranscriptomic methods. Samples will be banked for >5 years. Component A2: Serial blood samples will be collected, analyzed, and banked from 20% of participants in Component A1. Samples will be collected at enrollment, in the months flanking the respiratory infection season, before/after vaccinations, and after infection. Quantitative immunoassays for antigen-specific antibody (Ab) levels and neutralizing antibody (nAb) levels against contemporary circulating virus isolates will be performed. Component B: For >100 index cases from A1 per year, we will collect and test daily nasal swabs from >75% of household members for >2 weeks. A subset of swabs (including at least 1 per index case) will be analyzed by viral genome sequencing, and high-priority pathogens/variants will be cultured. For a subset of households, we will also explore the relationships between viral load (quantified by qPCR) and viral titer (by in vitro cell-based assay), and between viral culture positivity and transmission. Component C: We will serve as the Data Hub and Warehouse, and support protocol development across the network, provide data entry and management tools, analyze data; and develop dashboards/visualizations.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15272", "attributes": { "award_id": "1R01AA031252-01A1", "title": "Evaluating Telehealth Delivery of Brief Alcohol Screening and Intervention for College Students", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 26558, "first_name": "Bradley Townsend", "last_name": "Kerridge", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-20", "end_date": "2029-07-31", "award_amount": 708556, "principal_investigator": { "id": 31859, "first_name": "CLAYTON", "last_name": "NEIGHBORS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20520, "first_name": "Eric R.", "last_name": "Pedersen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 231, "ror": "https://ror.org/048sx0r50", "name": "University of Houston", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "The proposed research study will test the efficacy of a telehealth version of the Brief Alcohol Screening and Intervention for College Students (BASICS), which is the gold standard prevention and intervention approach to target heavy alcohol use on college campuses across the United States. BASICS in an NIAAA Tier 1 intervention which involves assessment of drinking behavior followed by a single in-person session in which personalized feedback is presented by a trained facilitator in a motivational interviewing (MI) style utilizing harm reduction principles to reduce risks and alcohol-related consequences. Alternative strategies requiring less time, effort, and resources, with no face-to-face interaction with a facilitator (e.g., web-based personalized feedback), have proven less effective. The in-person delivery format of BASICS has presented barriers to wider implementation due to the time, effort, and costs of traveling to and from sessions, the need for private meeting space, and the firmly fixed scheduling of intervention sessions. In the proposed study, we will evaluate the efficacy of a tele-BASICS approach utilizing the ZOOM application compared to in-person BASICS and a lower threshold treatment as usual intervention. Three hundred mandated and 300 volunteer students who report hazardous drinking will be recruited from two large universities and randomly assigned to a condition (in- person BASICS, Tele-BASICS, or treatment as usual). Follow-up assessments will occur 1-, 3-, 6-, and 12- months post-baseline. The significance of this research lies in the potential to maximize access to the highest standard of care by establishing support for easier access without sacrificing any central features of the traditional BASICS intervention. In addition, many universities pragmatically adapted existing in-person interventions to remote-telehealth approaches in response to the COVID pandemic but now have no scientific basis for determining whether transitioning back to in-person approaches would be beneficial. In addition to demonstrating non-inferiority to traditional BASICS, we expect Tele-BASICS to significantly outperform treatment as usual. Attention and working therapeutic alliance are expected to mediate intervention efficacy. We expect Tele-BASICS to have stronger effects than in-person BASICS among women, heavier drinkers, students without co-occurring substance use, and those with greater motivation. We expect higher Tele- BASICS participants recruitment and completion rates and lower costs relative to in-person BASICS. This research brings together a team of experienced investigators with a collaborative history and supports NIAAA's strategic plan to improve strategies to prevent and reduce harmful alcohol consumption in a high-risk population. The establishment of Tele-BASICS as an efficacious alternative to in-person BASICS would allow more schools to adopt BASICS as their standard of care – and potentially engage more students in empirically- supported treatment by decreasing barriers to care.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15274", "attributes": { "award_id": "1R13AI186419-01", "title": "24th Annual Rocky Mountain Virology Association Conference", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22573, "first_name": "Barbara L.", "last_name": "Mulach", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 7500, "principal_investigator": { "id": 24399, "first_name": "Rushika", "last_name": "Perera", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Program Summary / Abstract The Rocky Mountain Virology Association (RMVA) will hold its 24th annual meeting September 27th-29th, 2024. The meeting brings together regional and national investigators in virology and prion biology for a 3-day retreat- style conference with extensive interaction and collaboration. The original meeting was organized by investigators in Colorado and Wyoming interested in free and open exchange of scientific data and ideas in virology in a venue that promotes collaboration among students, post-docs and faculty. Specifically, our annual meeting at the CSU Mountain Campus encourages young scientists to present their research and receive feedback from established scientists. The goals are promotion of scientific interactions and training. A major benefit of participation has been the novel collaborations that arise between scientists in different disciplines. Topics discussed include medical virology (vaccines, epidemiology, viral zoonoses), arthropod-borne diseases (viruses, RNA metabolism, viral vectors and vector biology), host defenses (viral immunology and pathogenesis), prion biology, cancer biology and systems biology. Special sessions on vaccine development, pandemic viruses, virus discovery and the global impact of viral diseases have been common features. The 2021 meeting had a retrospective on the COVID-19 pandemic with discussions on successful approaches and establishment of systems for future challenges. The next meeting will feature discussions on Immune mechanisms of arthropod vectors, pathogen genomics, arenaviruses, filoviruses, coronaviruses, noroviruses, arboviruses (flaviviruses and alphaviruses), lentiviruses, prion diseases, paleovirology, neurobiology, host-pathogen interactions, virus latency, epigenetics and host response. The meeting offers excellent collaborative opportunities. Attendees include scientists from CSU, University of Colorado, University of Wyoming, University of Northern Colorado, the Centers for Disease Control (Fort Collins) and the Department of Agriculture Animal and Plant Health Inspection Service, regional biotech companies, and universities in Iowa, Idaho, Nebraska, Kansas, Montana, New Mexico and Utah. The RMVA was incorporated in 2010 as an educational charity (501(c)(3)). Our volunteer board of directors is charged with encouraging student and junior faculty involvement by minimizing costs as we encourage women and minorities to participate in all stages of program presentation and development. Our attendance is limited to a maximum of 125 individuals, and the growth of the meeting to capacity illustrates the desire of regional scientists to participate. Funds for this proposal are requested to provide minority grants and childcare, reduced registration fees for graduate students, post-doctoral fellows and early-stage investigators, and for travel and housing for seven invited speakers. Registration fees, charitable contributions, and sponsorships cover the base costs for the meeting. The RMVA has been a source of communication and collaboration in the Rocky Mountain region, with outreach across the nation, for twenty-three years. NIAID support has expanded meeting interest to national and international levels.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1404, "pages": 1424, "count": 14236 } } }